« Back to News
McKesson Designated by CMS as 2022 Qualified Clinical Data Registry
Seven custom measures receive approval, raising the bar on oncology patient care
IRVING, Texas, Feb. 8, 2022 — For the sixth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed℠ electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
As a CMS-approved QCDR, Practice Insights℠, a performance analytics tool powered by Ontada®, can collect and report clinical data on behalf of clinicians for both MIPS and custom QCDR quality measures to drive improvements in quality and cost of care.
“Being an approved QCDR has been a priority for Practice Insights so we can provide the most effective tool for practices participating in value-based care,” said Susan Shiff, president of Ontada, McKesson’s oncology real-world data and evidence, clinical education and provider technology business. “Practice Insights targets populations to assess performance across value-based care programs, and provides insight into the coordination, cost and value of patient care.”
Seven custom QCDR measures identified by physician leaders in The US Oncology Network and submitted by McKesson were approved by CMS. These include:
- COVID-19 vaccinations (NEW for 2022)
- Advance care planning in metastatic cancer patients
- Hepatitis B serology testing and prophylactic treatment prior to receiving anti-CD20 targeting drugs
- Mutation testing for lung cancer completed prior to start of targeted therapy
- Patient-reported pain improvement
- Supportive care drug utilization in last 14 days of life
- Utilization of granulocyte colony-stimulation factors (GCSF) in metastatic colorectal cancer
“Community practices work to improve patient care while also satisfying MIPS requirements for quality and value improvement,” said Lalan Wilfong, MD, vice president of Payer Solutions and Practice Transformation for The US Oncology Network, a network supported by McKesson of more than 1,400 independent, community-based physicians. “As we reach the two-year mark of the pandemic, we are particularly pleased that CMS supports our COVID-19 vaccination measure to assess vaccination rates in the high-risk oncology patient population.”
Along with The US Oncology Network, McKesson also supports oncology practices through its Onmark group purchasing organization (GPO), and the QCDR measure approvals reflect the organization’s insight into the entire landscape of oncology care.
“We are pleased to be once again recognized as a CMS-approved QCDR that collects, reports and analyzes medical data with the goal of improving patient care,” said Erin Crum, director of Quality Measurement Strategy for McKesson. “We are continually working with community practices so they can thrive in a value-based care environment and provide high-quality care. Additionally, we are committed to finding ways to help bridge the gap for patients impacted by social determinants of health, and we plan to focus on providing insight through advanced reporting and analytics in the upcoming year.”
About McKesson Corporation
McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful – all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.
Ontada® is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology and channels, which accelerate innovation for life sciences companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit ontada.com or follow @OntadaOncology.
About The US Oncology Network
Every day, The US Oncology Network (The Network) helps more than 1, 400 independent physicians deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.
Claire Crye, Public Relations